Lynn Anne Bristol

Array ( [id] => 20364105 [patent_doc_number] => 20250353917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-11-20 [patent_title] => EGFR BINDING COMPLEX AND METHOD OF MAKING AND USING THEREOF [patent_app_type] => utility [patent_app_number] => 18/027583 [patent_app_country] => US [patent_app_date] => 2021-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14027 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18027583 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482239 [patent_doc_number] => 20220089743 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE [patent_app_type] => utility [patent_app_number] => 17/477651 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69518 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17477651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19884176 [patent_doc_number] => 12269869 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof [patent_app_type] => utility [patent_app_number] => 17/461365 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 63 [patent_no_of_words] => 86935 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17461365 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895268 [patent_doc_number] => 20240010753 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => ANTI-ROR1 ANTIBODIES AND RELATED BISPECIFIC BINDING PROTEINS [patent_app_type] => utility [patent_app_number] => 18/042762 [patent_app_country] => US [patent_app_date] => 2021-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26118 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042762 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692635 [patent_doc_number] => 20230322955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION [patent_app_type] => utility [patent_app_number] => 18/042267 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586423 [patent_doc_number] => 20240383980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => CD3/CD25 Antibodies For Neuro-Immune Diseases [patent_app_type] => utility [patent_app_number] => 18/042144 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586423 [patent_doc_number] => 20240383980 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => CD3/CD25 Antibodies For Neuro-Immune Diseases [patent_app_type] => utility [patent_app_number] => 18/042144 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18692635 [patent_doc_number] => 20230322955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => ANTIGEN BINDING PROTEINS WITH NON-CANONICAL DISULFIDE IN FAB REGION [patent_app_type] => utility [patent_app_number] => 18/042267 [patent_app_country] => US [patent_app_date] => 2021-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21884 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370011 [patent_doc_number] => 20220025063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTS [patent_app_type] => utility [patent_app_number] => 17/405861 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17405861 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258491 [patent_doc_number] => 20210371476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => AFFINITY-ENHANCED MONMERIC STREPTAVIDIN CHIMERIC ANTIGEN RECEPTOR (CAR) [patent_app_type] => utility [patent_app_number] => 17/398311 [patent_app_country] => US [patent_app_date] => 2021-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27195 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17398311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612420 [patent_doc_number] => 20230279152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => ANTI-CLAUDIN 18.2 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/019728 [patent_app_country] => US [patent_app_date] => 2021-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019728 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895266 [patent_doc_number] => 20240010751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => MULTISPECIFIC BINDING AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/018864 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -193 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18895266 [patent_doc_number] => 20240010751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => MULTISPECIFIC BINDING AGENTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/018864 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 70874 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -193 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17505200 [patent_doc_number] => 20220098302 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-31 [patent_title] => COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/387399 [patent_app_country] => US [patent_app_date] => 2021-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15169 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17387399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612406 [patent_doc_number] => 20230279138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION [patent_app_type] => utility [patent_app_number] => 18/007012 [patent_app_country] => US [patent_app_date] => 2021-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18612406 [patent_doc_number] => 20230279138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-07 [patent_title] => NOVEL BISPECIFIC ANTI-CD3/CD20 POLYPEPTIDE COMPLEX FORMULATION [patent_app_type] => utility [patent_app_number] => 18/007012 [patent_app_country] => US [patent_app_date] => 2021-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39203 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18007012 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385610 [patent_doc_number] => 20220033462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => INHIBITORY CHIMERIC ANTIGEN RECEPTORS [patent_app_type] => utility [patent_app_number] => 17/385805 [patent_app_country] => US [patent_app_date] => 2021-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36170 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385805 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17414086 [patent_doc_number] => 20220048990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE [patent_app_type] => utility [patent_app_number] => 17/381145 [patent_app_country] => US [patent_app_date] => 2021-07-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39448 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17381145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343680 [patent_doc_number] => 20220010011 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/378070 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36644 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385645 [patent_doc_number] => 20220033497 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/378000 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36737 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378000 [rel_patent_id] =>[rel_patent_doc_number] =>)